Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Phase II Study With Irinotecan/Cetuximab (Until PD) Followed by XELOX/Cetuximab (Until PD) vs the Reverse Sequence in Metastatic CRC With Previous Benefit on Irinotecan/Bevacizumab Based Therapy

NCT00755534 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT00755534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00755534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Phase II Study With Irinotecan/Cetuximab (Until PD) Followed by XELOX/Cetuximab (Until PD) vs the Reverse Sequence in Metastatic CRC With Previous Benefit on Irinotecan/Bevacizumab Based Therapy
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2008
Completion date
November 30, 2008
Enrollment
68 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer